A Long Term Safety Study of BCX7353 in Hereditary Angioedema (APeX-S)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03472040
Recruitment Status : Recruiting
First Posted : March 21, 2018
Last Update Posted : November 7, 2018
Information provided by (Responsible Party):
BioCryst Pharmaceuticals

Brief Summary:
This is an open-label study to evaluate the long term safety and effectiveness of oral treatment with BCX7353 in preventing acute angioedema attacks in patients with Type I and Type II HAE.

Condition or disease Intervention/treatment Phase
Hereditary Angioedema HAE Prophylaxis Drug: BCX7353 Phase 2 Phase 3

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 160 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: An Open-label Study to Evaluate the Long-term Safety of Daily Oral BCX7353 in Subjects With Type I and II Hereditary Angioedema
Actual Study Start Date : February 16, 2018
Estimated Primary Completion Date : August 2019
Estimated Study Completion Date : August 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: BCX7353 110 mg once daily Drug: BCX7353
BCX7353 mg oral capsules administered once daily

Experimental: BCX7353 150 mg once daily Drug: BCX7353
BCX7353 mg oral capsules administered once daily

Primary Outcome Measures :
  1. The long term safety of oral BCX7353 capsules [ Time Frame: 48 weeks ]
    The number and percentage of subjects with treatment-emergent adverse events

Secondary Outcome Measures :
  1. The rate of acute attacks of angioedema during treatment [ Time Frame: 48 weeks ]
  2. The durability of response to treatment [ Time Frame: 48 weeks ]
    To evaluate if the rate of attacks remains consistent (durable) over time

  3. Patient reported quality of life (QoL) during treatment [ Time Frame: 48 weeks ]
    To measure changes in quality of life over time from baseline, assessed by use of an HAE-specific Angioedema QoL (AE-QoL) questionnaire

  4. Patient's satisfaction with medication during long term administration of BCX7353 [ Time Frame: 48 weeks ]
    To measure satisfaction with study medication using the Treatment Satisfaction Questionnaire for Medication (TSQM)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Gender Based Eligibility:   Yes
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  • Subjects with HAE Type I or II who either have participated in a previous BCX7353 study or, in selected countries, in the opinion of the Investigator are expected to derive benefit from an oral treatment for the prevention of angioedema attacks.
  • Access to appropriate medication for treatment of acute attacks
  • Acceptable effective contraception
  • Written informed consent

Key Exclusion Criteria:

  • Pregnancy or breast-feeding
  • Any clinically significant medical condition or medical history that, in the opinion of the Investigator or Sponsor, would interfere with the subject's safety or ability to participate in the study
  • Any laboratory parameter abnormality that, in the opinion of the Investigator, is clinically significant and relevant for this study
  • Discontinuation of study drug due to a hypersensitivity reaction BCX7353 in a prior study
  • Severe hypersensitivity to multiple medicinal products or severe hypersensitivity/ anaphylaxis with unclear etiology
  • Unacceptable noncompliance in a previous BCX7353 study (if applicable) as assessed by the Sponsor or Investigator
  • Investigational drug exposure, other than BCX7353, within 30 days prior to the screening visit (or baseline if no screening visit)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03472040

Contact: Study director +1 919 859 1302

  Show 45 Study Locations
Sponsors and Collaborators
BioCryst Pharmaceuticals
Principal Investigator: Henriette Farkas, MD Semmelweis University, Budapest, Hungary

Responsible Party: BioCryst Pharmaceuticals Identifier: NCT03472040     History of Changes
Other Study ID Numbers: BCX7353-204
First Posted: March 21, 2018    Key Record Dates
Last Update Posted: November 7, 2018
Last Verified: November 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes

Keywords provided by BioCryst Pharmaceuticals:
Hereditary Angioedema

Additional relevant MeSH terms:
Angioedemas, Hereditary
Vascular Diseases
Cardiovascular Diseases
Skin Diseases, Vascular
Skin Diseases
Hypersensitivity, Immediate
Immune System Diseases
Genetic Diseases, Inborn